Seven-year surveillance of nosocomial invasive aspergillosis in a French University Hospital

Garnaud, Cécile; Brenier-Pinchart, Marie-Pierre; Thiébaut-Bertrand, Anne; Hamidfar, Rébecca; Quésada, Jean-Louis; Bosseray, A.; Lebeau, B.; Mallaret, Marie-Reine; Maubon, Danièle; Saint-Raymond, Christel; Pinel, Claudine; Hincky, Virginie; Plantaz, Dominique; Cornet, Muriel; Pelloux, Hervé

doi:10.1016/j.jinf.2012.08.006

Cited by 23 publications

(17 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The follow-up period was defined as the time elapsed between the initiation of POS therapy and the last determination of the POS C min . All cases were prospectively reviewed monthly by a multidisciplinary team including chest physicians, a microbiologist, a hygienist, and a pharmacologist (29). Cases were classified according to guidelines from the European Organization for Research and Treatment of Cancer/European Invasive Infections Cooperative Group and the criteria of the National Institute of Allergy and Infectious Diseases-Mycoses Study Group (EORTC/MSG) (30).…”

Section: Methodsmentioning

confidence: 99%

Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations

Gautier-Veyret

Bolcato

Roustit

et al. 2019

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

The delayed-release tablet formulation of posaconazole (POS-tab) results in higher plasma POS trough concentrations (C min ) than the oral suspension (POS-susp), which raises the question of the utility of therapeutic drug monitoring (TDM). We aimed to compare the variability of the POS C min for the two formulations and identify determinants of the POS-tab C min and its variability. Demographic, biological, and clinical data from 77 allogeneic hematopoietic stem cell transplant patients (874 C min ) treated with POS-tab (n ϭ 41), POS-susp (n ϭ 29), or both (n ϭ 7) from January 2015 to December 2016 were collected retrospectively. Interpatient and within-subject coefficients of variation (CVs) of the C min adjusted to dose (D) were calculated for each formulation. Between-group comparisons were performed using a linear mixed effects model. The POS C min was higher for the tablet than for the suspension (median [25th-75th percentile]: 1.8 [1.2-2.4] mg/liter versus 1.2 [0.7-1.6] mg/liter, P Ͻ 0.0001). Interpatient CVs for the tablet and suspension were 60.8 versus 63.5% (P ϭ 0.7), whereas within-subject CVs were 39.7 and 44.9%, respectively (P ϭ 0.3). Univariate analysis showed that age and treatment by POS-tab were significantly and positively associated with the POS C min , whereas diarrhea was associated with a diminished POS C min . Multivariate analysis identified treatment with POS-tab and diarrhea as independent factors of the POS C min , with a trend toward a lower impact of diarrhea during treatment with POS-tab (P ϭ 0.07). Despite increased POS exposure with the tablet formulation, the variability of the POS C min was not significantly lower than that of the suspension. This suggests that TDM may still be useful to optimize tablet POS therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations

Gautier-Veyret

Bolcato

Roustit

et al. 2019

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…patients were divided into one of two groups, the Aspergillus disease or Aspergillus colonization group, based on clinical, radiological, mycological, and serological criteria (Table 1). These criteria are a combination of those used in each of the participating centers (12)(13)(14) and those described in the literature (1,2,15 (ii) Aspergillus Western blot IgG kit. Each serum was tested using the Asp-WB IgG kit (LDBio Diagnostics, Lyon, France) according to the manufacturer's instructions.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of the Aspergillus Western Blot IgG Kit for Diagnosis of Chronic Aspergillosis

Oliva

Flori

Hennequin³

et al. 2015

J Clin Microbiol

View full text Add to dashboard Cite

“…A working group composed of medical mycologists, infection control physicians and clinicians was created in 2000 in our hospital. The objective of the Aspergillosis Committee (AC) was management of IA and CPA . The laboratory registers notifications of cases defined by microbiologic or serological signs of aspergillosis infections (presence of hyphae or Aspergillus positive culture, Aspergillus ‐positive antibody reaction or positive Aspergillus antigenemia).…”

Section: Methodsmentioning

confidence: 99%

Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry

Camara

Reymond

Saint-Raymond

et al. 2014

Clinical Respiratory J

Self Cite

View full text Add to dashboard Cite

show abstract

Seven-year surveillance of nosocomial invasive aspergillosis in a French University Hospital

Cited by 23 publications

References 34 publications

Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations

Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations

Evaluation of the Aspergillus Western Blot IgG Kit for Diagnosis of Chronic Aspergillosis

Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry

Contact Info

Product

Resources

About